Multiplex Lateral Flow Immunoassay: An Overview of Strategies Towards High-Throughput Point-of-Need Testing

Anfossi, Laura; Nardo, Fabio Di; Cavalera, Simone; Giovannoli, Cristina; Baggiani, Claudio

doi:10.20944/preprints201811.0405.v1

Cited by 46 publications

(27 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Over the decades of application, these test systems have passed the test of time and confirmed their wide availability, high speed of detection, ease of operation and readout of results, and efficient and reliable diagnosis of diseases [21] , [23] – [25] . The cost efficiency and easy-to-handle property of these portable diagnostic systems are fully consistent with the world's modern concept of ‘point-of-care testing’ (laboratory testing at the site of treatment).…”

Section: Lfia-platforms: Types and Formatsmentioning

confidence: 99%

“…To date, the classical microbiological and immunoserological methods, as well as modern diagnostic platforms such as enzyme immunoassay (EIA) and chemiluminescence assay, polymerase chain reaction (PCR), flow cytometry, and mass spectrometry (MALDI), have been used to accurately identify molecular markers. However, these diagnostic tools requiring expensive equipment, long testing time, and qualified personnel are not always available for small local hospitals, especially in conditions of limited budget and decentralized infrastructure of medical units [3] , [11] , [20] , [21] .…”

Section: Lateral Flow Immunoassay (Lfia)mentioning

confidence: 99%

“…The potential of these recently introduced efficient technologies consists in the continuous development and improvement of the existing numerous LFIA-platforms, as well as in the creation of multiplex formats and complication of diagnostic goals (such as, e.g., cancer screening). Moreover, the absence of need for special temperature storage conditions contributes to the expansion of the range of their use in developing countries and in sparsely populated and remote regions [15] , [16] , [21] , [22] .…”

Section: Lfia-platforms: Types and Formatsmentioning

confidence: 99%

“…The key parameters that characterize properties of this material are the capillary forces and the ease of binding and subsequent immobilization of proteins involved in further reactions. The pore size of the membranes is from 0.05 to 12 µm, which provides the required rate, time, and uniformity of capillary flow, the most important characteristics determining the quality of test systems [3] , [31] – [34] .…”

Section: Lfia-platforms: Types and Formatsmentioning

confidence: 99%

See 3 more Smart Citations

Six decades of lateral flow immunoassay: from determining metabolic markers to diagnosing COVID-19

2020

View full text Add to dashboard Cite

Technologies based on lateral flow immunoassay (LFIA), known in some countries of the world as immunochromatographic tests, have been successfully used for the last six decades in diagnostics of many diseases and conditions as they allow rapid detection of molecular ligands in biosubstrates. The popularity of these diagnostic platforms is constantly increasing in healthcare facilities, particularly those facing limited budgets and time, as well as in household use for individual health monitoring. The advantages of these low-cost devices over modern laboratory-based analyzers come from their availability, opportunity of rapid detection, and ease of use. The attractiveness of these portable diagnostic tools is associated primarily with their high analytical sensitivity and specificity, as well as with the easy visual readout of results. These qualities explain the growing popularity of LFIA in developing countries, when applied at small hospitals, in emergency situations where screening and monitoring health condition is crucially important, and as well as for self-testing of patients. These tools have passed the test of time, and now LFIA test systems are fully consistent with the world's modern concept of ‘point-of-care testing’, finding a wide range of applications not only in human medicine, but also in ecology, veterinary medicine, and agriculture. The extensive opportunities provided by LFIA contribute to the continuous development and improvement of this technology and to the creation of new-generation formats. This review will highlight the modern principles of design of the most widely used formats of test-systems for clinical laboratory diagnostics, summarize the main advantages and disadvantages of the method, as well as the current achievements and prospects of the LFIA technology. The latest innovations are aimed at improving the analytical performance of LFIA platforms for the diagnosis of bacterial and viral infections, including COVID-19.

show abstract

Section: Lfia-platforms: Types and Formatsmentioning

confidence: 99%

Section: Lateral Flow Immunoassay (Lfia)mentioning

confidence: 99%

Section: Lfia-platforms: Types and Formatsmentioning

confidence: 99%

Section: Lfia-platforms: Types and Formatsmentioning

confidence: 99%

See 2 more Smart Citations

Six decades of lateral flow immunoassay: from determining metabolic markers to diagnosing COVID-19

2020

View full text Add to dashboard Cite

show abstract

“…Due to increased quantity of controlled compounds in medical diagnostics, food safety and ecological monitoring, there is a need for multiplex test systems. The location of several binding lines with reactants of different specificity is the best technological solution for multiplex ICA [6][7][8][9]. Such tests for 2-8 analytes are widely used to determine antibiotics in milk, mycotoxins in grain, etc.…”

Section: Introductionmentioning

confidence: 99%

Design of Multiplex Lateral Flow Tests: A Case Study for Simultaneous Detection of Three Antibiotics

Bartosh

Sotnikov

Hendrickson

et al. 2019

Preprint

View full text Add to dashboard Cite

The presented study is focused on the impact of binding zones locations at immunochromatographic test strips into analytical parameters of multiplex lateral flow assay. Due to non-equilibrium conditions for such assays the duration of immune reactions influences significantly on analytical parameters, and the integration of several analytes into one multiplex strip may cause essential decrease of sensitivity. To choose the best location of binding zones, we have tested reactants for immunochromatographic assays of lincomycin, chloramphenicol, and tetracycline. The influence of the distance to the binding zones on the intensity of coloration and limit of detection (LOD) was rather different. Basing on the obtained data, the best order of binding zones was chosen. In comparison with non-optimal location the LODs were 5-10 fold improved. The final assay provides LODs 0.4, 0.4 and 1.0 ng/mL for lincomycin, chloramphenicol, and tetracycline, respectively. The proposed approach can be applied for multiassays of other analytes.

show abstract

Biomarker based biosensors: An opportunity for diagnosis of COVID‐19

Khaksarinejad

Arabpour

Rezakhani

et al. 2022

Reviews in Medical Virology

View full text Add to dashboard Cite

Early diagnosis and treatment of diseases are crucial research areas of human health. For early diagnosis, one method that has proven efficient is the detection of biomarkers which can provide real‐time and accurate biological information. Most biomarker detection is currently carried out at localised dedicated laboratories using large and automated analysers, increasing waiting time and costs. Smaller, faster, and cheaper devices could potentially replace these time‐consuming laboratory analyses and make analytical results available as point‐of‐care diagnostics. Innovative biosensor‐based strategies could allow biomarkers to be tested reliably in a decentralised setting. Early diagnosis of COVID‐19 patients has a key role in order to use quarantine and treatment strategies in a timely manner. Raised levels of several biomarkers in COVID‐19 patients are associated with respiratory infections or dysfunction of various organs. Through clinical studies of COVID‐19 patient biomarkers such as ferritin, Interleukins, albumin and …are found to reveals significant differences in their excretion ranges from healthy patients and patients with SARS‐CoV‐2, in addition to the development of biomarkers based biosensor such as stated biomarkers can be used and to investigate more specific biomarkers further proteomic analysis can be performed. This review presents several biomarker alterations in COVID‐19 patients such as salivary, circulatory, coagulation, cardiovascular, renal, liver, C‐reactive protein (CRP), immunological and inflammatory biomarkers. Also, biomarker sensors based on electrochemical, optical, and lateral flow characteristics which have potential applications for SARS‐COV‐2 in the recent COVID‐19 pandemic, will be discussed.

show abstract

Multiplex Lateral Flow Immunoassay: An Overview of Strategies Towards High-Throughput Point-of-Need Testing

Cited by 46 publications

References 48 publications

Six decades of lateral flow immunoassay: from determining metabolic markers to diagnosing COVID-19

Six decades of lateral flow immunoassay: from determining metabolic markers to diagnosing COVID-19

Design of Multiplex Lateral Flow Tests: A Case Study for Simultaneous Detection of Three Antibiotics

Biomarker based biosensors: An opportunity for diagnosis of COVID‐19

Contact Info

Product

Resources

About